LONDON (Reuters)—AstraZeneca’s hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. Amgen, its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab after suicidal…
Approval Expected for Apremilast
New drug shows promise in treating psoriatic arthritis, ankylosing spondylitis & psoriasis
Joint Smart Coalition Takes on Psoriasis in New York City
The Arthritis Foundation and the National Psoriasis Foundation launched the Joint Smart Coalition to focus on patient education, resources, and outreach. At a coalition-sponsored community-outreach event at Queens College in Flushing, N.Y., attendees were provided information on setting goals, stretching techniques, easy exercises, treatment options, and tips for a healthy lifestyle. (posted Dec. 13)
Susceptibility Loci Shed Light on Fundamental Pathways of Psoriasis
Investigators have described 15 new psoriasis susceptibility loci. The loci highlight the importance of the skin in both acquired and innate host defense and identify the innate immune response as a key factor in psoriasis.
A Unique Structure for Tackling Psoriatic Disease
GRAPPA brings together a group of highly motivated physicians to address these complex disorders
- « Previous Page
- 1
- …
- 6
- 7
- 8